Literature DB >> 35290483

The impact of low serum cholinesterase levels on survival in patients with colorectal cancer.

Yasuhiro Takano1, Koichiro Haruki2, Shu Tsukihara1, Daisuke Ito1, Hironori Kanno1, Kyonsu Son1, Nobuyoshi Hanyu1, Ken Eto3.   

Abstract

PURPOSE: Nutritional and inflammatory status have been associated with postoperative recurrence and poor survival in patients with colorectal cancer. The aim of the present study is to investigate the relationship between serum cholinesterase levels and postoperative outcomes among patients who underwent curative resection for colorectal cancer.
METHODS: The study comprised 174 patients who had undergone curative resection for colorectal cancer. We explored the relationship between preoperative serum cholinesterase levels and disease-free survival and overall survival after curative resection. Then patients were divided into the high-cholinesterase group (n = 102) and the low-cholinesterase group (n = 72) to analyze their clinicopathological variables including other nutritional markers and systemic inflammatory responses.
RESULTS: In multivariate analysis, lymph node metastasis (P = 0.011) and serum cholinesterase levels (P < 0.01) were independent predictors of disease-free survival, while lymph node metastasis (P = 0.013), serum cholinesterase levels (P < 0.01), and carbohydrate antigen19-9 (P = 0.022) were independent predictors of overall survival. In the low-cholinesterase group, neutrophil to lymphocyte ratio, (P = 0.021), C-reactive protein to albumin ratio (P < 0.01), and distant metastasis (P < 0.01) were higher, and prognostic nutritional index (P < 0.01) was lower compared with the high-cholinesterase group.
CONCLUSION: Preoperative low serum cholinesterase levels can be a prognostic factor for postoperative recurrence and poor prognosis in patients after curative resection for colorectal cancer, suggesting an important role of cholinesterase in the assessment of nutritional and inflammatory status in cancer patients.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Cholinesterase; Colorectal cancer; Survival

Mesh:

Substances:

Year:  2022        PMID: 35290483     DOI: 10.1007/s00384-022-04119-5

Source DB:  PubMed          Journal:  Int J Colorectal Dis        ISSN: 0179-1958            Impact factor:   2.796


  21 in total

1.  Half-lives of albumin and cholinesterase in critically ill patients.

Authors:  Thomas Gamsjäger; Lydia Brenner; Christian Sitzwohl; Christian Weinstabl
Journal:  Clin Chem Lab Med       Date:  2008       Impact factor: 3.694

2.  Patterns of metachronous metastases after curative treatment of colorectal cancer.

Authors:  Yvette R B M van Gestel; Ignace H J T de Hingh; Myrthe P P van Herk-Sukel; Felice N van Erning; Laurens V Beerepoot; Jan H Wijsman; Gerrit D Slooter; Harm J T Rutten; Geert-Jan M Creemers; Valery E P P Lemmens
Journal:  Cancer Epidemiol       Date:  2014-05-17       Impact factor: 2.984

3.  Low level of pseudocholinesterase in patient with Crohn's disease.

Authors:  S N Khalil; S J Dudrick; A Mathieu; B M Rigor; E P Fody
Journal:  Lancet       Date:  1980-08-02       Impact factor: 79.321

4.  Serum cholinesterase is an excellent biomarker of liver cirrhosis.

Authors:  Jeyamani Ramachandran; K G Sajith; Sophiya Priya; Amit K Dutta; K A Balasubramanian
Journal:  Trop Gastroenterol       Date:  2014 Jan-Mar

5.  Alterations of serum cholinesterase in patients with gastric cancer.

Authors:  Shan-Zhi Gu; Xin-Han Zhao; Ping Quan; Sheng-Bin Li; Bo-Rong Pan
Journal:  World J Gastroenterol       Date:  2005-08-07       Impact factor: 5.742

6.  [Protein-energy malnutrition: its effects on 4 metabolic parameters].

Authors:  E Camarero González; V Muñoz Leira; M Iglesias Guerrero; J A Fernández Alvarez; J Cabezas-Cerrato
Journal:  Nutr Hosp       Date:  1995 May-Jun       Impact factor: 1.057

7.  Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.

Authors:  Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray
Journal:  Int J Cancer       Date:  2014-10-09       Impact factor: 7.396

Review 8.  AChE Inhibition-based Multi-target-directed Ligands, a Novel Pharmacological Approach for the Symptomatic and Disease-modifying Therapy of Alzheimer's Disease.

Authors:  Yu Wang; Hao Wang; Hong-zhuan Chen
Journal:  Curr Neuropharmacol       Date:  2016       Impact factor: 7.363

9.  Prognostic Significance of Serum Cholinesterase Level in Patients With Acute Decompensated Heart Failure With Preserved Ejection Fraction: Insights From the PURSUIT-HFpEF Registry.

Authors:  Masahiro Seo; Takahisa Yamada; Shunsuke Tamaki; Shungo Hikoso; Yoshio Yasumura; Yoshiharu Higuchi; Yusuke Nakagawa; Masaaki Uematsu; Haruhiko Abe; Hisakazu Fuji; Toshiaki Mano; Daisaku Nakatani; Masatake Fukunami; Yasushi Sakata
Journal:  J Am Heart Assoc       Date:  2019-12-18       Impact factor: 5.501

10.  Th17-type cytokines, IL-6 and TNF-α synergistically activate STAT3 and NF-kB to promote colorectal cancer cell growth.

Authors:  V De Simone; E Franzè; G Ronchetti; A Colantoni; M C Fantini; D Di Fusco; G S Sica; P Sileri; T T MacDonald; F Pallone; G Monteleone; C Stolfi
Journal:  Oncogene       Date:  2014-09-01       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.